Bicyclic piperazines as metabotropic glutatmate receptor antagonists
申请人:Edwards Louise
公开号:US20070037816A1
公开(公告)日:2007-02-15
The invention relates to compounds of formula I or pharmaceutically acceptable salts or solvates thereof:
where Ar
1
, A, Hy, R
1
, m and n are as defined in the description. The invention also includes pharmaceutical compositions and uses of, and processes of making the compounds, as well as methods of medical treatment of mGluR5-mediated disorders.
Bicyclic Piperazines as Metabotropic Glutatmate Receptor Antagonists
申请人:Edwards Louise
公开号:US20080312240A1
公开(公告)日:2008-12-18
The invention relates to compounds of formula I or pharmaceutically acceptable salts or solvates thereof:
where Ar
1
, A, Hy, R
1
, m and n are as defined in the description. The invention also includes pharmaceutical compositions and uses of, and processes of making the compounds, as well as methods of medical treatment of mGluR5-mediated disorders.
BICYCLIC PIPERAZINES AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS
申请人:AstraZeneca AB
公开号:EP1919911A1
公开(公告)日:2008-05-14
[EN] BICYCLIC PIPERAZINES AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS<br/>[FR] PIPERAZINES BICYCLIQUES EN TANT QU'AGENTS ANTAGONISTES DE RECEPTEUR DE GLUTAMATE METABOTROPIQUE
申请人:ASTRAZENECA AB
公开号:WO2007021574A1
公开(公告)日:2007-02-22
[EN] The invention relates to compounds of formula I or pharmaceutically acceptable salts or solvates thereof: where Ar1, A Hy, R1, m and n are as defined in the description. The invention also includes pharmaceutical compositions and uses of, and processes of making the compounds, as well as methods of medical treatment of mGluR5-mediated disorders. [FR] L'invention concerne des composés de formule I ou des sels pharmaceutiquement acceptables ou des solvates de ceux-ci: où Ar1, A Hy, R1, m et n sont tels que définis dans la description. L'invention porte également sur des compositions pharmaceutiques et des utilisations de celles-ci, sur des procédés de fabrication desdits composés ainsi que sur des procédés de traitement médical de troubles médiés par mGluR5.